Raymond James Financial Inc. bought a new position in shares of Vericel Co. (NASDAQ:VCEL - Free Report) during the 4th quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor bought 512,219 shares of the biotechnology company's stock, valued at approximately $28,126,000. Raymond James Financial Inc. owned approximately 1.04% of Vericel as of its most recent filing with the Securities & Exchange Commission.
Several other institutional investors and hedge funds have also recently bought and sold shares of VCEL. Atria Investments Inc raised its stake in Vericel by 21.6% in the third quarter. Atria Investments Inc now owns 7,768 shares of the biotechnology company's stock valued at $328,000 after buying an additional 1,378 shares during the period. Victory Capital Management Inc. grew its position in Vericel by 2.0% during the third quarter. Victory Capital Management Inc. now owns 623,627 shares of the biotechnology company's stock worth $26,348,000 after buying an additional 12,481 shares in the last quarter. Zions Bancorporation N.A. grew its position in Vericel by 18.6% during the third quarter. Zions Bancorporation N.A. now owns 31,879 shares of the biotechnology company's stock worth $1,347,000 after buying an additional 4,993 shares in the last quarter. RiverPark Advisors LLC boosted its holdings in shares of Vericel by 124.5% in the 3rd quarter. RiverPark Advisors LLC now owns 5,572 shares of the biotechnology company's stock valued at $235,000 after purchasing an additional 3,090 shares in the last quarter. Finally, Meeder Asset Management Inc. acquired a new stake in shares of Vericel in the 3rd quarter valued at $92,000.
Wall Street Analysts Forecast Growth
VCEL has been the subject of a number of research reports. Truist Financial reiterated a "buy" rating and issued a $61.00 price target (down from $67.00) on shares of Vericel in a research note on Monday, March 3rd. Canaccord Genuity Group increased their price target on Vericel from $64.00 to $67.00 and gave the company a "buy" rating in a research note on Monday, February 3rd. HC Wainwright reaffirmed a "buy" rating and set a $60.00 target price on shares of Vericel in a research report on Friday, February 28th. BTIG Research raised their target price on Vericel from $56.00 to $66.00 and gave the stock a "buy" rating in a research report on Tuesday, November 26th. Finally, StockNews.com raised Vericel from a "sell" rating to a "hold" rating in a research report on Saturday, March 8th. One equities research analyst has rated the stock with a hold rating and seven have assigned a buy rating to the company. According to data from MarketBeat.com, the stock has a consensus rating of "Moderate Buy" and a consensus target price of $62.29.
Get Our Latest Stock Report on Vericel
Vericel Trading Down 2.7 %
VCEL stock traded down $1.30 during trading on Tuesday, reaching $46.30. 529,170 shares of the stock were exchanged, compared to its average volume of 376,757. The firm's 50 day moving average is $55.39 and its 200 day moving average is $51.82. Vericel Co. has a twelve month low of $39.12 and a twelve month high of $63.00. The firm has a market cap of $2.31 billion, a P/E ratio of 771.80 and a beta of 1.78.
Insiders Place Their Bets
In other news, Director Robert L. Md Zerbe sold 2,500 shares of the company's stock in a transaction that occurred on Wednesday, February 5th. The stock was sold at an average price of $62.50, for a total value of $156,250.00. Following the completion of the transaction, the director now directly owns 26,595 shares of the company's stock, valued at $1,662,187.50. This represents a 8.59 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, insider Jonathan Siegal sold 1,092 shares of the company's stock in a transaction that occurred on Wednesday, February 5th. The shares were sold at an average price of $61.99, for a total value of $67,693.08. Following the completion of the transaction, the insider now directly owns 1,206 shares of the company's stock, valued at approximately $74,759.94. This represents a 47.52 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last ninety days, insiders sold 34,092 shares of company stock valued at $1,683,582. Corporate insiders own 5.20% of the company's stock.
About Vericel
(
Free Report)
Vericel Corporation, a commercial-stage biopharmaceutical company, engages in the research, development, manufacture, and distribution of cellular therapies for sports medicine and severe burn care markets in North America. The company markets autologous cell therapy products comprising MACI, an autologous cultured chondrocytes on porcine collagen membrane for the repair of symptomatic, and single or multiple full-thickness cartilage defects of the knee; Epicel, a permanent skin replacement humanitarian use device for the treatment of adult and pediatric patients with deep-dermal or full-thickness burns; and NexoBrid, a biological orphan product for eschar removal in adults with deep partial-thickness and/or full-thickness thermal burns.
Featured Articles
Before you consider Vericel, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Vericel wasn't on the list.
While Vericel currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Thinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
